Trial Profile
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- 05 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
- 06 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Dec 2023.
- 30 Nov 2020 Planned End Date changed from 1 Oct 2020 to 1 Oct 2023.